Biogen Inc.
Biogen Reports Q4 and Full-Year 2024 Financial Results and Provides 2025 Guidance
Summary
Biogen Inc. announced its financial results for the fourth quarter and full year 2024, showing a 3% growth in total revenue year-over-year for Q4 and a 2% decline for the full year. GAAP diluted EPS increased by 7% for Q4 and 40% for the full year, while Non-GAAP diluted EPS grew by 17% for Q4 and 12% for the full year. The company also provided its financial guidance for 2025, expecting Non-GAAP diluted EPS between $15.25 and $16.25, with total revenue expected to decline by a mid-single digit percentage at constant currency compared to 2024.
Profitelligence Alerts
Get alerts for BIIB
Be first to know when Biogen Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Official SEC Documents
Advertisement